WASHINGTON, March 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading ...

Danaher (DHR) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this industrial and medical device maker have returned +0.4% over the past month versus the Zacks S&P 500 composite's +3.6% change. The Zacks Diversified Operations industry, to which Danaher belongs, has gained 6.5% over this period. Now the key question is: Where could the stock be headed in ...

Danaher (DHR) closed the most recent trading day at $251.47, moving +0.83% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.63% for the day. Meanwhile, the Dow experienced a rise of 0.2%, and the technology-dominated Nasdaq saw an increase of 0.82%.The industrial and medical device maker's shares have seen a decrease of 0.24% over the last month, not keeping up with the Conglomerates sector's gain of 5.08% and the S&P 500's gain of 1.76%.Analysts and investors ...

Group 1: Company Performance - Danaher Corporation (DHR) is experiencing growth in its Life Sciences segment, driven by stable demand in academic and life science research markets, particularly for plasmids, proteins, and gene editing solutions [1] - The company has seen positive market responses to new products like IDBS' Polar Insight and Molecular Devices' CellXpress.ai, which enhance drug discovery processes [1] - In the Diagnostics unit, new solutions such as Beckman Coulter's DxI 9000 immunoassay analyzer are gaining traction [1] Group 2: Acquisitions and Financials - Danaher acquired Abcam plc for $5.7 billion in December 2023, which is expected to enhance its Life Sciences segment and address significant healthcare challenges [2] - The acquisition contributed to a 0.5% increase in total revenues for Danaher in 2023 [2] - The company paid dividends of $821 million in 2023, a 0.4% increase year-over-year, and raised its dividend by 12.5% to 27 cents per share in February 2024 [2] Group 3: Segment Challenges - The Biotechnology and Diagnostics segments are facing challenges, with revenues declining by 11.5% and 18% year-over-year, respectively, due to reduced demand for COVID-related products [4] - High debt levels are a concern, with Danaher reporting long-term debt of $16.7 billion and current liabilities of $8.3 billion, exceeding cash equivalents of $5.9 billion [4] Group 4: Market Comparison - Over the past three months, Danaher has gained 10.4%, outperforming the industry growth of 5.9% [4]

Company Performance - Danaher (DHR) closed at $252.80, reflecting a -0.35% change from the previous day, underperforming the S&P 500's 0.11% loss [1] - Over the past month, Danaher's shares appreciated by 4.42%, underperforming the Conglomerates sector's gain of 7.86% but outperforming the S&P 500's gain of 2.7% [1] - Upcoming earnings per share (EPS) are projected to be $1.74, indicating a 26.27% decrease from the same quarter last year, with revenue forecasted at $5.64 billion, a 21.31% decline compared to the prior year [1] Annual Estimates - Zacks Consensus Estimates for the annual period anticipate earnings of $7.63 per share and revenue of $24.09 billion, reflecting shifts of +0.66% and -12.73% from the last year [2] - Recent adjustments to analyst estimates for Danaher indicate changing near-term business trends, with positive revisions suggesting analysts' confidence in the company's performance [2] Valuation Metrics - Danaher has a Forward P/E ratio of 33.25, which is a premium compared to the industry's average Forward P/E of 17.86 [3] - The company currently has a PEG ratio of 3.85, compared to the industry's average PEG ratio of 2.25 [3] - The Diversified Operations industry, part of the Conglomerates sector, holds a Zacks Industry Rank of 51, placing it within the top 21% of over 250 industries [3]

Summary of Danaher Corporation's Conference Call Company Overview - **Company**: Danaher Corporation (NYSE:DHR) - **Event**: TD Cowen 44th Annual Health Care Conference - **Date**: March 5, 2024 - **Participants**: Rainer Blair (President, CEO), Dan Brennan (TD Cowen) Key Points Industry and Market Dynamics - The healthcare and life sciences industry is experiencing volatility, with Danaher aiming for a steady-state growth rate in the high single digits, despite market challenges [3][4] - Danaher has transformed its portfolio by creating new public companies (Envista and Veralto) and making strategic acquisitions (Aldevron and Abcam) to enhance growth [4][5] - The respiratory business has seen significant growth, increasing from approximately $250 million pre-pandemic to an estimated $1.2 billion, indicating strong long-term sustainability [5] Financial Performance and Outlook - Danaher has maintained a cash conversion rate of over 100% for over 30 years, contributing to its earnings power and sustainable value creation [6] - The company anticipates a low single-digit decline in core organic growth for 2024, with expectations of recovery in the second half of the year [12][24] - The diagnostics business is expected to grow, supported by strong patient volumes returning to pre-pandemic levels [15] Inventory and Supply Chain Management - Danaher has focused on improving inventory visibility and management to mitigate supply chain disruptions, which has been a learning experience from the pandemic [11][20] - The company has paused cancellation fees for customers to encourage inventory destocking, aiming for a clearer understanding of true demand [19][20] Regional Insights - The outlook for China remains cautious, with expectations of mid- to high teens decline in bioprocessing, while global markets are projected to experience flat to low single-digit contraction [25][26] - Long-term growth in China is expected to be in the low double digits, reflecting a more sustainable growth rate compared to historical performance [51][52] Innovation and Product Development - Danaher has accelerated R&D investments, launching new products such as the DxI 9000 immuno-analyzer and CellXpress.ai, which leverage AI for cell line development [9] - The company is seeing strong growth in its molecular diagnostics segment, particularly with the GeneXpert system, which has expanded its installed base significantly [41][42] M&A Strategy - Danaher remains active in pursuing M&A opportunities, with a disciplined approach to ensure financial models show appropriate returns [53][54] Conclusion - Danaher Corporation is navigating a complex market landscape with a focus on portfolio transformation, innovation, and strategic management of resources. The company is positioned for future growth despite current challenges, with a strong emphasis on maintaining operational efficiency and customer satisfaction.

Danaher (DHR) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this industrial and medical device maker have returned +3.3% over the past month versus the Zacks S&P 500 composite's +5.2% change. The Zacks Diversified Operations industry, to which Danaher belongs, has gained 6.7% over this period. Now the key question is: Where could the stock be headed in the near term?Althoug ...

A month has gone by since the last earnings report for Danaher (DHR) . Shares have added about 6.6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Danaher due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Danaher Q4 Earnings Beat, Biotechnology Sales Dip Y/YDanaher’s ...

Danaher (DHR) ended the recent trading session at $255.71, demonstrating a +0.33% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 0.17%. Elsewhere, the Dow lost 0.06%, while the tech-heavy Nasdaq lost 0.55%.The industrial and medical device maker's shares have seen an increase of 4.05% over the last month, not keeping up with the Conglomerates sector's gain of 7.17% and outstripping the S&P 500's gain of 3.98%.The investment community will be paying ...

WASHINGTON, Feb. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (Danaher) announced today it has committed to set science-based greenhouse gas (GHG) emission reduction targets in line with the Science Based Targets initiative (SBTi), including a long-term target to reach net-zero value chain emissions by no later than 2050. Danaher's pledge encompasses Scope 1, 2 and 3 GHG emissions and complements its existing commitment to reduce Scope 1 and 2 GHG emissions on an absolute basis by 50.4% by 2032 ...